Developer docs
API playgroundTry for free, no card

Search company profiles

Volta Medical

Full company profile

uuid0000j51

Namestring
Volta Medical
Legal namestring
Volta Medical
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Volta Medical is a French-founded medtech company (Marseille, 2016) developing AI-guided software to assist cardiac electrophysiologists during atrial fibrillation (AF) ablation procedures. Its core technology is proprietary spatio-temporal dispersion mapping, which analyzes intracardiac electrogram signals in real time to identify ablation targets in complex and persistent AF cases. The company markets two principal products: VOLTA VX1 (its initial FDA-cleared AI software for cardiac arrhythmias) and the current-generation AF-Xplorer II, which is FDA 510(k)-cleared and CE-marked, features high stability analysis, expanded catheter compatibility (including Medtronic's Sphere-9), and integrates with GE HealthCare's CardioLab AltiX AI.i EP recording system.

Volta generates revenue through hardware/medical-device sales of AF-Xplorer II systems and integrated software solutions delivered via its GE HealthCare channel partnership, with pricing negotiated quote-by-quote through enterprise field sales. Its primary customers are hospitals and electrophysiology departments treating AF patients, with end users being interventional cardiologists and cardiac electrophysiologists performing catheter ablations, particularly for persistent and recurrent cases where empirical strategies underperform.

The company is venture-backed (Series B of €36M in January 2023 led by Vensana Capital with Gilde Healthcare and Lightstone Ventures), holds a dual US (FDA) and EU (CE) regulatory footprint, and has established US operations in Providence, Rhode Island to support its November 2025 commercial US launch. Clinical evidence is the core commercial asset: the RESTART trial demonstrated 83% AF-freedom at 12 months after a single procedure, and the TAILORED-AF randomized trial (370 patients across Europe and US) achieved 88% AF-freedom versus 70% with standard pulmonary vein isolation — the first Level 1 evidence of improved efficacy for persistent AF in EP history.

Short descriptiontext

Volta Medical is an AI-driven medtech company that develops FDA-cleared and CE-marked software (VX1, AF-Xplorer II) using spatio-temporal dispersion mapping to guide electrophysiologists during atrial fibrillation ablation procedures, serving hospitals and EP labs across Europe and the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMarseille, France
HQ citystring
Marseille
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac electrophysiology software, AI ablation guidance, atrial fibrillation mapping, interventional cardiology AI, cardiac electrogram analysis
Industry2 codes
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAC
Electrophysiology (Heart Rhythm)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cardiac Electrophysiology AI Software
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales
TypeHardware Sales
Description

Sale of AI-powered medical devices and systems (VX1, AF-Xplorer II) to hospitals and electrophysiology departments for use in cardiac ablation procedures.

buff.ly
2Integrated Software Solutions
TypeLicensing Royalties
Description

Revenue from integrated AI software solutions sold in partnership with GE HealthCare, combining proprietary AI mapping with third-party recording systems.

prnewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1VOLTA VX1
Description

AI software for cardiac arrhythmias

buff.ly
+2 more records
Core offering1 text field

Volta Medical develops AI-powered software that assists electrophysiologists during catheter ablation procedures for atrial fibrillation. Its flagship Volta AF-Xplorer II system identifies spatio-temporal dispersed electrograms in real time, integrating with EP recording systems (GE HealthCare CardioLab) and supporting multiple catheter types to provide objective, AI-driven guidance for ablation target identification in complex and persistent AF cases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 83% freedom from atrial fibrillation at 12 months after single procedure (RESTART trial)
+3 more records
Product overview1 text field

Volta Medical is a medtech company offering AI-guided electrophysiology software. Its portfolio centers on the AF-Xplorer II system (the current-generation product), which integrates with GE HealthCare's CardioLab recording platform and supports multiple catheter types including Medtronic's Sphere-9. An earlier version branded as VOLTA VX1 served as the initial FDA-cleared AI software for cardiac arrhythmias. Both products are built on spatio-temporal dispersion mapping AI to guide catheter ablation for atrial fibrillation.

Product and service2 records
1Volta AF-Xplorer II
CategoryCardiac Electrophysiology AI Mapping Software
Description

A next-generation AI-enhanced mapping solution that assists electrophysiologists in real-time assessment of complex atrial fibrillation by identifying spatio-temporal dispersed electrograms during catheter ablation procedures. Features high stability analysis, expanded catheter compatibility (including Medtronic Sphere-9), and integration with GE HealthCare's CardioLab AltiX AI.i recording system. FDA 510(k)-cleared and CE-marked.

2VOLTA VX1
CategoryCardiac Electrophysiology AI Mapping Software
Description

AI software for cardiac arrhythmias designed to assist physicians in identifying dispersed electrograms during ablation procedures for atrial fibrillation. FDA 510(k)-cleared. The initial product that established Volta Medical's presence in AI-guided electrophysiology and drove the company's Series B funding.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-18
Description

Volta Medical and GE HealthCare announced successful US launch of integrated AI-driven electrophysiology solutions, combining Volta's AF-Xplorer II system with GE HealthCare's CardioLab AltiX AI.i EP recording system. The integrated solution provides electrophysiologists with advanced signal clarity and AI-driven insights for complex atrial fibrillation ablation procedures.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Biosense Webster (Johnson & Johnson)
TypeBroad incumbent
Description

Johnson & Johnson's EP subsidiary and global market leader in cardiac ablation. Competes with Volta via the CARTO 3 electroanatomical mapping system and ablation catheters, and is the largest incumbent Volta must displace or partner with in EP labs.

2Abbott
TypeBroad incumbent
Description

Global medtech incumbent with the EnSite X EP mapping system and TactiFlex ablation catheter portfolio. Directly competes in AF ablation procedure guidance and has the installed-base and KOL relationships that define Volta's competitive set.

TypeBroad incumbent
Description

Major EP player with the Rhythmia HDx mapping system and FARAPULSE pulsed-field ablation platform. Competes in the same AF ablation workflows as Volta and is rapidly expanding its AI-guided mapping capabilities.

TypeBroad incumbent
Description

Global medtech leader in EP with the Sphere-9 catheter (which Volta's AF-Xplorer II is now compatible with) and Affera mapping/primo ablation system. Both a potential channel partner and a vertically integrated competitor in AI-guided AF ablation.

TypeOthers
Description

Volta's strategic integration partner for the CardioLab AltiX AI.i EP recording system. Comparable in that both serve electrophysiology labs with integrated hardware/software solutions, but operates as a complementary channel rather than a direct AI mapping competitor.

6Acutus Medical
TypeDirect peer
Description

EP-focused company developing mapping and ablation technologies for arrhythmia treatment. Directly comparable as an AI-enabled mapping competitor targeting similar electrophysiologist customers in catheter ablation.

TypeEmerging player
Description

Developer of the Globe Mapping and Ablation System for AF treatment. Targets the same AF ablation procedure workflow as Volta with a single-catheter mapping-and-ablation approach, addressing a partially overlapping customer base.

8Adagio Medical
TypeEmerging player
Description

Clinical-stage company developing pulsed-field and ultra-low-temperature cryoablation for persistent AF. Addresses the same persistent AF patient population where Volta's clinical evidence is strongest.

TypeEmerging player
Description

Developer of robotic magnetic navigation systems for EP procedures. Adjacent competitor in the procedure-guidance layer of AF ablation, with potential to integrate or compete with AI mapping software.

TypeEmerging player
Description

Developer of the ECGenius electrophysiology recording and AI analysis system. Targets similar electrophysiologist customers with AI-augmented signal interpretation, though more focused on recording than mapping/guidance.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Volta Medical

Cardiac Electrophysiology AI Softwarevolta-medical.com

Volta Medical is an AI-driven medtech company that develops FDA-cleared and CE-marked software (VX1, AF-Xplorer II) using spatio-temporal dispersion mapping to guide electrophysiologists during atrial fibrillation ablation procedures, serving hospitals and EP labs across Europe and the United States.

What Volta Medical does

Volta Medical is a French-founded medtech company (Marseille, 2016) developing AI-guided software to assist cardiac electrophysiologists during atrial fibrillation (AF) ablation procedures. Its core technology is proprietary spatio-temporal dispersion mapping, which analyzes intracardiac electrogram signals in real time to identify ablation targets in complex and persistent AF cases. The company markets two principal products: VOLTA VX1 (its initial FDA-cleared AI software for cardiac arrhythmias) and the current-generation AF-Xplorer II, which is FDA 510(k)-cleared and CE-marked, features high stability analysis, expanded catheter compatibility (including Medtronic's Sphere-9), and integrates with GE HealthCare's CardioLab AltiX AI.i EP recording system.

Volta generates revenue through hardware/medical-device sales of AF-Xplorer II systems and integrated software solutions delivered via its GE HealthCare channel partnership, with pricing negotiated quote-by-quote through enterprise field sales. Its primary customers are hospitals and electrophysiology departments treating AF patients, with end users being interventional cardiologists and cardiac electrophysiologists performing catheter ablations, particularly for persistent and recurrent cases where empirical strategies underperform.

The company is venture-backed (Series B of €36M in January 2023 led by Vensana Capital with Gilde Healthcare and Lightstone Ventures), holds a dual US (FDA) and EU (CE) regulatory footprint, and has established US operations in Providence, Rhode Island to support its November 2025 commercial US launch. Clinical evidence is the core commercial asset: the RESTART trial demonstrated 83% AF-freedom at 12 months after a single procedure, and the TAILORED-AF randomized trial (370 patients across Europe and US) achieved 88% AF-freedom versus 70% with standard pulmonary vein isolation — the first Level 1 evidence of improved efficacy for persistent AF in EP history.

Volta Medical firmographics

Firmographics
Name
Volta Medical
Legal name
Volta Medical
Website
https://volta-medical.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
101–250 employees
Short description
Volta Medical is an AI-driven medtech company that develops FDA-cleared and CE-marked software (VX1, AF-Xplorer II) using spatio-temporal dispersion mapping to guide electrophysiologists during atrial fibrillation ablation procedures, serving hospitals and EP labs across Europe and the United States.
Ownership category
akta.pro rank

Volta Medical industry classification

Industry
Product category
Cardiac Electrophysiology AI Software
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAC
Electrophysiology (Heart Rhythm)

Keywords

  • Cardiac electrophysiology software
  • AI ablation guidance
  • Atrial fibrillation mapping
  • Interventional cardiology AI
  • Cardiac electrogram analysis

Where Volta Medical is headquartered

Location

Headquarters

HQ city
Marseille
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Volta Medical business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Medical Device Sales: Sale of AI-powered medical devices and systems (VX1, AF-Xplorer II) to hospitals and electrophysiology departments for use in cardiac ablation procedures.
  2. Integrated Software Solutions: Revenue from integrated AI software solutions sold in partnership with GE HealthCare, combining proprietary AI mapping with third-party recording systems.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Volta Medical product offering

Product offering

Core offering

Volta Medical develops AI-powered software that assists electrophysiologists during catheter ablation procedures for atrial fibrillation. Its flagship Volta AF-Xplorer II system identifies spatio-temporal dispersed electrograms in real time, integrating with EP recording systems (GE HealthCare CardioLab) and supporting multiple catheter types to provide objective, AI-driven guidance for ablation target identification in complex and persistent AF cases.

Product overview

Volta Medical is a medtech company offering AI-guided electrophysiology software. Its portfolio centers on the AF-Xplorer II system (the current-generation product), which integrates with GE HealthCare's CardioLab recording platform and supports multiple catheter types including Medtronic's Sphere-9. An earlier version branded as VOLTA VX1 served as the initial FDA-cleared AI software for cardiac arrhythmias. Both products are built on spatio-temporal dispersion mapping AI to guide catheter ablation for atrial fibrillation.

Differentiator

Problem solved

Functional benefit

Brands

  • VOLTA VX1: AI software for cardiac arrhythmias
  • Volta AF-Xplorer II
  • VX1

Products and services

  • Volta AF-Xplorer II A next-generation AI-enhanced mapping solution that assists electrophysiologists in real-time assessment of complex atrial fibrillation by identifying spatio-temporal dispersed electrograms during catheter ablation procedures. Features high stability analysis, expanded catheter compatibility (including Medtronic Sphere-9), and integration with GE HealthCare's CardioLab AltiX AI.i recording system. FDA 510(k)-cleared and CE-marked.
  • VOLTA VX1 AI software for cardiac arrhythmias designed to assist physicians in identifying dispersed electrograms during ablation procedures for atrial fibrillation. FDA 510(k)-cleared. The initial product that established Volta Medical's presence in AI-guided electrophysiology and drove the company's Series B funding.

Quantifiable outcome

  • 83% freedom from atrial fibrillation at 12 months after single procedure (RESTART trial)
  • +3 more outcomes

Companies that use Volta Medical

Customer profile

Segments2 records

Ideal customer profiles2 records

Volta Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature3 records

Volta Medical partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • GE HealthCarecoreTechnology or Integration · 18 November 2025Volta Medical and GE HealthCare announced successful US launch of integrated AI-driven electrophysiology solutions, combining Volta's AF-Xplorer II system with GE HealthCare's CardioLab AltiX AI.i EP recording system. The integrated solution provides electrophysiologists with advanced signal clarity and AI-driven insights for complex atrial fibrillation ablation procedures.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Volta Medical competitors and assessment

Company assessment

Broad incumbents

  • Biosense Webster (Johnson & Johnson): Johnson & Johnson's EP subsidiary and global market leader in cardiac ablation. Competes with Volta via the CARTO 3 electroanatomical mapping system and ablation catheters, and is the largest incumbent Volta must displace or partner with in EP labs.
  • Abbott: Global medtech incumbent with the EnSite X EP mapping system and TactiFlex ablation catheter portfolio. Directly competes in AF ablation procedure guidance and has the installed-base and KOL relationships that define Volta's competitive set.
  • Boston Scientific: Major EP player with the Rhythmia HDx mapping system and FARAPULSE pulsed-field ablation platform. Competes in the same AF ablation workflows as Volta and is rapidly expanding its AI-guided mapping capabilities.
  • Medtronic: Global medtech leader in EP with the Sphere-9 catheter (which Volta's AF-Xplorer II is now compatible with) and Affera mapping/primo ablation system. Both a potential channel partner and a vertically integrated competitor in AI-guided AF ablation.

Others

  • GE HealthCare: Volta's strategic integration partner for the CardioLab AltiX AI.i EP recording system. Comparable in that both serve electrophysiology labs with integrated hardware/software solutions, but operates as a complementary channel rather than a direct AI mapping competitor.

Direct peers

  • Acutus Medical: EP-focused company developing mapping and ablation technologies for arrhythmia treatment. Directly comparable as an AI-enabled mapping competitor targeting similar electrophysiologist customers in catheter ablation.

Emerging players

  • Kardium: Developer of the Globe Mapping and Ablation System for AF treatment. Targets the same AF ablation procedure workflow as Volta with a single-catheter mapping-and-ablation approach, addressing a partially overlapping customer base.
  • Adagio Medical: Clinical-stage company developing pulsed-field and ultra-low-temperature cryoablation for persistent AF. Addresses the same persistent AF patient population where Volta's clinical evidence is strongest.
  • Stereotaxis: Developer of robotic magnetic navigation systems for EP procedures. Adjacent competitor in the procedure-guidance layer of AF ablation, with potential to integrate or compete with AI mapping software.
  • CathVision: Developer of the ECGenius electrophysiology recording and AI analysis system. Targets similar electrophysiologist customers with AI-augmented signal interpretation, though more focused on recording than mapping/guidance.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

Volta Medical social profiles

Digital presence

Volta Medical compliance and trust

Trust signal

Compliance2 records

Volta Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Volta Medical leadership team

Management profile

Number of profiles

Profiles3 records

Volta Medical funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Volta Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Volta Medical

What does Volta Medical do?

Volta Medical develops AI-powered software that assists electrophysiologists during catheter ablation procedures for atrial fibrillation. Its flagship Volta AF-Xplorer II system identifies spatio-temporal dispersed electrograms in real time, integrating with EP recording systems (GE HealthCare CardioLab) and supporting multiple catheter types to provide objective, AI-driven guidance for ablation target identification in complex and persistent AF cases.

Is Volta Medical a public or private company?

Volta Medical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Volta Medical founded?

Volta Medical was founded in 2016. It employs 101 to 250 people.

Where is Volta Medical based?

Volta Medical is headquartered in Marseille, France, in the Europe region.

How does Volta Medical make money?

Two revenue lines are on record. Medical Device Sales are the primary driver. The others are integrated Software Solutions.

Who are Volta Medical's main competitors?

Broad incumbents on record are Biosense Webster (Johnson & Johnson), Abbott, Boston Scientific and Medtronic. GE HealthCare is listed as an others. Acutus Medical is listed as a direct peer. Emerging players are Kardium, Adagio Medical, Stereotaxis and CathVision.

Does Volta Medical have an API?

No public API is recorded for Volta Medical.

What industry is Volta Medical in?

Volta Medical's product category is Cardiac Electrophysiology AI Software. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems, with a secondary code of HLAKABAC, Electrophysiology (Heart Rhythm). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarVolta Medical Announces Activities at Heart Rhythm Society 2026 in Chicago, IL, USAVolta Medical announced its participation at the Heart Rhythm Society 2026 Annual Meeting in Chicago from April 23–26, where the company will showcase its Volta AF-Xplorer™ II AI-enhanced mapping solution across multiple scientific sessions. The company will host a Rhythm Theater session featuring an expert panel and deliver a podium presentation by Chief Medical Officer Dr. Jérôme Kalifa. The FDA 510(k)-cleared and CE-marked device assists electrophysiologists in identifying spatio-temporal dispersed electrograms during catheter ablation procedures for complex atrial fibrillation.PR NewswireVolta Medical Announces Activities at Heart Rhythm Society 2026 in Chicago, IL, USAVolta Medical announced its participation in the Heart Rhythm Society 2026 Annual Meeting in Chicago, April 23–26, featuring multiple scientific presentations and an exhibit showcasing its AI technology. The company will present its Volta AF-Xplorer™ II solution, an FDA 510(k) cleared and CE marked AI companion for electrophysiologists that identifies spatio-temporal dispersed electrograms during catheter ablation procedures for complex atrial fibrillation. A Rhythm Theater session will feature an internationally recognized panel of electrophysiology leaders discussing AI-enhanced substrate mapping for challenging AF patient populations.PR NewswireDie RESTART-Studie von Volta Medical liefert vielversprechende Ergebnisse für KI-Lösungen bei wiederkehrendem VorhofflimmernVolta Medical announced results from the RESTART study, published in Heart Rhythm, showing their AI solution achieved 83% freedom from atrial fibrillation 12 months after a single procedure in patients with recurrent AF and isolated pulmonary veins who had prior ablation. The prospective, multicenter clinical trial included patients with treatment-resistant conditions, with 45% having undergone two or more previous ablations, and demonstrated 70% freedom from atrial arrhythmia compared to historical success rates of 29–37% with empirical strategies. The study highlights the potential of AI-guided dispersion mapping to improve outcomes in one of the most challenging patient populations in cardiac electrophysiology.PR NewswireL'essai RESTART de Volta Medical produit des résultats prometteurs pour les solutions IA dans la fibrillation auriculaire récurrenteVolta Medical announced positive results from the RESTART clinical trial, published in Heart Rhythm, demonstrating that its AI solution achieved 83% freedom from atrial fibrillation at 12 months after a single procedure in patients with recurrent AF and isolated pulmonary veins following prior ablation. The trial, which enrolled 45% of patients who had undergone two or more prior ablations, showed significantly higher success rates compared to the 29-37% historically reported with empirical treatment strategies. The AI-guided approach also produced a 19.7-point improvement in quality-of-life scores as measured by the AFEQT questionnaire, exceeding the clinically significant threshold of five points.PR NewswireEl ensayo RESTART de Volta Medical muestra resultados prometedores para fibrilación auricularVolta Medical announced positive results from the RESTART clinical trial, showing 83% freedom from atrial fibrillation at 12 months after a single procedure using their AI-based solution in patients with recurrent AF and isolated pulmonary veins after prior ablation. The trial enrolled a highly complex population where 45% of patients had undergone two or more prior ablations, significantly outperforming historical rates of 29-37% with empirical strategies. The AI solution, AF-Xplorer™ II, received FDA 510(k) clearance and European CE marking for helping electrophysiologists identify dispersive electrograms during ablation procedures.PR NewswireVolta Medical's RESTART Trial Shows Promising Findings for AI Solutions in Recurrent Atrial FibrillationVolta Medical announced results from the RESTART trial, published in Heart Rhythm, demonstrating that their AI solution for spatio-temporal dispersion mapping achieved 83% freedom from atrial fibrillation at 12 months after a single procedure in patients with recurrent AF and isolated pulmonary veins. The trial showed 70% freedom from any atrial arrhythmia after one procedure, compared to historically poor outcomes of 29%-37% with empirical strategies in similar populations. The study enrolled a highly treatment-resistant cohort with 45% of patients having undergone two or more prior ablations.PR NewswireVolta Medical's RESTART Trial Shows Promising Findings for AI Solutions in Recurrent Atrial FibrillationVolta Medical announced results from the RESTART trial, published in Heart Rhythm, showing their AI solution for spatio-temporal dispersion mapping achieved 83% freedom from atrial fibrillation at 12 months in patients with recurrent AF and isolated pulmonary veins who had previously undergone ablation. The trial demonstrated 70% freedom from any atrial arrhythmia after one procedure, significantly outperforming the 29%-37% success rates reported in prior studies using empirical strategies in similar treatment-resistant populations. The RESTART trial is the first prospective, multicenter study to evaluate this AI-guided approach, with findings to be presented at AF Symposium in February 2026.BioSpaceVolta Medical’s RESTART Trial Shows Promising Findings for AI Solutions in Recurrent Atrial FibrillationVolta Medical announced positive results from the RESTART trial, published in Heart Rhythm, demonstrating that their AI solution for spatio-temporal dispersion mapping achieved 83% freedom from atrial fibrillation at 12 months after a single procedure in patients with recurrent AF and isolated pulmonary veins following prior ablation. The trial also showed 70% freedom from any atrial arrhythmia after one procedure, compared to 29%-37% success rates in prior studies using empirical strategies, and a 19.7-point improvement in quality-of-life scores exceeding clinically meaningful thresholds. The multicenter prospective study enrolled a highly treatment-resistant cohort, with 45% of patients having undergone two or more prior ablations, positioning Volta's AI-guided approach as a potential advancement for a population historically facing poor outcomes.PR NewswireVolta Medical and GE HealthCare Announce Successful U.S. Launch of Joint AI-Driven Electrophysiology SolutionsVolta Medical and GE HealthCare announced the U.S. launch of their jointly developed AI-driven electrophysiology solutions, integrating Volta's AF-Xplorer II system with GE's CardioLab AltiX AI.i. This collaboration aims to improve workflows and access to data for atrial fibrillation (AF) procedures. The combined solutions will be demonstrated at the upcoming Rhythm Interventions Online Symposium.YahooVolta Medical and GE HealthCare Announce Successful U.S. Launch of Joint AI-Driven Electrophysiology SolutionsVolta Medical and GE HealthCare have successfully launched their first joint AI-driven electrophysiology solution in the U.S., integrating Volta's AF-Xplorer™ II system with GE HealthCare's CardioLab™ AltiX AI.i recording system. The combined solution aims to provide electrophysiologists with advanced signal clarity and AI-driven insights to better navigate complex atrial fibrillation ablation procedures. The first presentation of the integrated solution is scheduled for the Rhythm Interventions Online Symposium on November 23, 2025.